Supplements

How Often Should IGF-1 Be Tested?

IGF-1 is one of the most stable and informative longevity biomarkers available, yet most people either never test it or test it far too frequently. Getting the cadence right — matched to your clinical context — is what separates useful data from expensive noise.

Jared Murray ·Co-Founder & Head of Health Research, Ones · ·9 min read
IGF-1growth hormonebiomarker testinglab testinglongevityhormones
How Often Should IGF-1 Be Tested?

How Often Should IGF-1 Be Tested?

For most healthy adults, once per year is a reasonable testing frequency — but the right answer depends heavily on context. If you have symptoms of growth hormone dysregulation, are managing a chronic condition, or have recently changed a diet or supplement protocol that influences IGF-1, retesting every three to six months gives more actionable data. People with known pituitary disorders or active cancer surveillance follow stricter schedules set by their physician.

What Is IGF-1 and Why Does It Matter?

Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone produced primarily in the liver in response to growth hormone (GH) signaling. Unlike GH itself, which pulses throughout the day in 4–8 discrete secretory bursts, IGF-1 circulates at relatively stable concentrations — which is exactly what makes it a superior biomarker. A single blood draw accurately reflects integrated GH secretion over days rather than capturing a single pulse.

IGF-1 mediates most of the anabolic effects traditionally attributed to GH: muscle protein synthesis, bone mineralization, cellular proliferation, and metabolic regulation. It binds to IGF-1 receptors on nearly every tissue type, making it relevant to contexts far beyond pediatric growth medicine — including metabolic health, cardiovascular risk stratification, cognitive aging, and longevity research. The IGF-1 receptor shares significant structural homology with the insulin receptor, which partly explains why states of chronic hyperinsulinemia tend to co-elevate IGF-1, and why fasting and caloric restriction reliably suppress it even when GH secretion remains intact.

Reference ranges are age- and sex-adjusted because IGF-1 peaks during puberty (roughly ages 14–17) and declines progressively through adulthood — at approximately 1–2% per year after age 30, mirroring the decline in GH pulse amplitude. A 55-year-old with an IGF-1 of 120 ng/mL sits squarely in a normal range; that same number would signal a problem in a 17-year-old.

IGF-1 Blood Test: What the Draw Actually Measures

The IGF-1 blood test is a serum assay, typically drawn fasting or under standardized conditions because recent high-carbohydrate or high-protein meals can transiently shift IGF-1. Most commercial labs (Quest Diagnostics, LabCorp) report results alongside age- and sex-matched reference intervals.

Key pre-test considerations:

  • Fasting for at least 8 hours is recommended at many labs, though some studies suggest the effect of a single meal is modest (less than 10% variation).
  • Acute illness, prolonged fasting (>24 hours), or severe caloric restriction suppresses IGF-1 independently of GH status.
  • Extreme exercise in the 24 hours prior can transiently elevate results.
  • Some medications — insulin, estrogen, corticosteroids — alter IGF-1 independent of pituitary function.

When tracking IGF-1 serially, drawing under consistent conditions (same lab, same fasting duration, same time of day) reduces noise and makes trend interpretation more reliable. The intra-individual coefficient of variation for IGF-1 on a single immunoassay platform is typically 5–8%, meaning changes smaller than that threshold may reflect assay noise rather than a genuine physiological shift — a practical argument against testing more than once every 8–12 weeks except in acute clinical scenarios.

Typical adult reference ranges by decade (approximate):

Age RangeLow (ng/mL)Normal (ng/mL)High (ng/mL)
20–29<115115–307>307
30–39<100100–267>267
40–49<8888–233>233
50–59<7171–200>200
60–69<5858–172>172
70+<4646–150>150

Ranges vary by laboratory and assay method. Always interpret against the reference interval provided by your specific lab.

How Often Should IGF-1 Be Tested? A Decision Framework

There is no universal guideline equivalent to the American Diabetes Association's annual HbA1c recommendation — IGF-1 testing frequency is individualized. The following framework synthesizes clinical endocrinology practice and preventive-medicine principles:

Scenario 1 — Healthy adult, no symptoms, general longevity monitoring

Once per year as part of a comprehensive metabolic panel is sufficient. IGF-1 declines gradually (roughly 1–2% per year after age 30), so quarterly testing in asymptomatic individuals generates noise without actionable signal.

Scenario 2 — Investigating symptoms of growth hormone deficiency or excess

Baseline plus a follow-up at 3 months after any intervention (dietary change, medication, peptide protocol). If the follow-up confirms the trajectory, annual monitoring resumes.

Scenario 3 — Managing diagnosed GH deficiency on GH replacement therapy

Every 3–6 months per Endocrine Society guidelines (Molitch et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21602453). The goal is to titrate GH dose to maintain IGF-1 within the age-adjusted normal range without overshoot. In the KIMS pharmacoepidemiological study — the largest real-world GH replacement registry — mean IGF-1 SDS was used as the primary dosing endpoint in over 13,000 patients, reinforcing the biomarker's clinical utility for treatment monitoring (Abs et al., Journal of Clinical Endocrinology & Metabolism 2006; PMID: 16608896).

Scenario 4 — Cancer surveillance or history of acromegaly

Frequency is set by the treating oncologist or endocrinologist. High IGF-1 is associated with colorectal, breast, and prostate cancer risk in epidemiological data (Renehan et al., Lancet 2004; PMID: 15016485), though IGF-1 alone is not a cancer screening tool.

Scenario 5 — Tracking a lifestyle, dietary, or supplement intervention

Baseline → 8–12 weeks post-intervention → assess. This interval aligns with hepatic IGF-1 synthesis kinetics and is long enough for most nutritional interventions to show a measurable effect. For example, controlled trials examining the effect of protein supplementation on IGF-1 have used 8–12 week windows as the minimum duration to detect statistically significant changes in serum IGF-1 (Holt et al., European Journal of Clinical Nutrition 2003; PMID: 12947434).

If you're also monitoring cardiovascular risk markers, pairing your IGF-1 panel with lipid biomarkers makes sense — see the guide on how often LDL should be tested for context on building an integrated testing schedule. Similarly, elevated fasting glucose often co-occurs with high-normal IGF-1 through shared insulin-resistance pathways; the article on how often fasting glucose should be tested covers the complementary retesting logic.

Symptoms of Low IGF-1

Below-range IGF-1 — sometimes called somatotropin deficiency when GH is involved — produces a recognizable clinical picture, though the symptoms overlap with hypothyroidism, low testosterone, and other deficiency states, which is why a blood test is essential for differentiation.

Common symptoms of low IGF-1 in adults include:

  • Persistent fatigue and reduced stamina disproportionate to activity level
  • Loss of lean muscle mass and increased central adiposity despite unchanged diet
  • Reduced bone mineral density and increased fracture risk
  • Impaired recovery from exercise or injury
  • Cognitive fog, reduced working memory, and low mood
  • Decreased libido
  • Thin, dry skin and reduced collagen density

A landmark study by Johannsson and colleagues demonstrated that GH-deficient adults had significantly impaired quality of life across all these domains, and that GH replacement normalizing IGF-1 improved body composition, bone density, and self-reported well-being (Johannsson et al., Journal of Clinical Endocrinology & Metabolism 1996; PMID: 8855804). Specifically, after 12 months of GH replacement targeting age-adjusted IGF-1, lean body mass increased by approximately 3–4 kg while fat mass decreased by a comparable amount, and bone turnover markers improved significantly.

Nutritional causes of low IGF-1 are common and underappreciated. Protein restriction, prolonged caloric deficit, and zinc deficiency all suppress hepatic IGF-1 production independent of GH status. A foundational review by Thissen et al. documented that dietary protein is the primary nutritional modulator of IGF-1, with low-protein diets reducing IGF-1 by 30–40% even when caloric intake is adequate (Thissen et al., Endocrine Reviews 1994; PMID: 8156941). The mechanism involves downregulation of GH receptor expression in the liver and reduced JAK2-STAT5 signaling — the intracellular cascade that drives IGF-1 transcription — when amino acid availability is insufficient. This matters because correcting a nutritional cause costs nothing and requires no prescription. Understanding related micronutrient shortfalls is worth reviewing — zinc deficiency symptoms and immune function covers how zinc interacts with growth hormone signaling in useful detail.

CRP elevation often accompanies states of low IGF-1, since chronic inflammation suppresses the GH–IGF-1 axis at the hepatic level through interleukin-1β and TNF-α signaling, which directly inhibit GH receptor expression. If you're investigating low IGF-1, checking your inflammatory markers in parallel adds important context — the guide on how often CRP should be tested explains the optimal retesting cadence.

Symptoms of High IGF-1

Below-range IGF-1 gets more clinical attention, but symptoms of high IGF-1 — particularly chronically elevated levels — carry their own risks that often go underrecognized in the functional medicine space.

Pathologically elevated IGF-1 is the hallmark of acromegaly (excess GH from a pituitary adenoma), but milder functional elevations occur with high dairy intake, elevated insulin states, obesity-associated insulin resistance, and exogenous GH or IGF-1 peptide use.

Symptoms and signs associated with elevated IGF-1:

  • Coarsening of facial features, enlarged hands and feet (in frank acromegaly)
  • Excessive sweating and oily skin
  • Joint pain and carpal tunnel syndrome
  • Fatigue paradoxically coexisting with elevated anabolic hormone levels
  • Headaches (pituitary pressure in acromegaly)
  • Increased soft tissue and organ growth
  • Elevated fasting glucose and insulin resistance

At the epidemiological level, men in the top quartile of IGF-1 had a relative risk of prostate cancer 2.4 times higher than those in the bottom quartile in the landmark Renehan et al. meta-analysis cited earlier. Similar associations were found for colorectal cancer in both sexes across 21 prospective studies. This does not make IGF-1 a clinical cancer test, but it does underscore why indefinitely high IGF-1 — sometimes promoted in performance circles as categorically desirable — requires a more nuanced interpretation.

Functionally elevated IGF-1 without clear pituitary pathology is increasingly observed in people following very high-protein diets (>2.5 g/kg body weight), particularly from animal sources, alongside high insulin load. A 2017 epidemiological analysis found that plant-based protein sources raised IGF-1 significantly less than equivalent quantities of animal protein, with dairy protein appearing to be the strongest dietary driver of circulating IGF-1 in adults (Levine et al., Cell Metabolism 2014; PMID: 24606898). This has practical implications: if your IGF-1 is persistently high-normal without a prescription drug or peptide explanation, a dietary audit before retesting in 8–12 weeks is warranted before escalating to endocrinology referral.

In people with insulin resistance, the relationship between IGF-1 and blood glucose regulation is bidirectional. Because IGF-1 has insulin-mimetic effects through shared receptor signaling, chronically supraphysiologic IGF-1 can paradoxically worsen fasting glucose by down-regulating pancreatic beta-cell insulin secretion through negative feedback. Pairing an IGF-1 retest with a fasting glucose and fasting insulin panel captures this interaction cleanly.

What This Means for Your Formula

IGF-1 is not a direct supplement target in the way that, say, thyroid hormones respond to selenium. However, several modifiable inputs that influence IGF-1 do fall within the scope of a personalized supplement protocol.

Zinc is perhaps the most direct micronutrient modulator of IGF-1. Zinc is required for GH receptor dimerization and downstream JAK2 kinase activation — the same pathway that drives hepatic IGF-1 synthesis. Studies in zinc-deficient adolescents and young adults show that repletion raises IGF-1 meaningfully even without changes in GH secretion itself. Ones includes zinc as a standalone ingredient dosed to clinical ranges, with amounts calibrated to the individual's serum zinc level and dietary intake pattern rather than applied as a blanket dose.

Vitamin D3 + K2 (MK-7) supports IGF-1 biology through a separate mechanism: vitamin D receptor signaling in the pituitary modulates GH pulse amplitude, and observational data consistently show positive correlations between 25-OH-D status and serum IGF-1 in adults over 50. Ones pairs D3 with MK-7 to support the vascular and bone co-factors that IGF-1 targets — particularly relevant for the low-IGF-1 phenotype where bone turnover and arterial calcification risk both shift unfavorably.

Omega-3 fatty acids (EPA/DHA) do not directly raise or lower IGF-1, but they modulate the inflammatory cytokines — particularly IL-6 and TNF-α — that suppress hepatic GH receptor expression and therefore limit IGF-1 output in chronically inflamed individuals. Reducing that inflammatory suppression is one plausible mechanism by which Omega-3 supplementation indirectly supports healthier IGF-1 expression in people with elevated CRP. Ones includes pharmaceutical-grade EPA/DHA dosed based on the individual's omega-3 index from wearable and lab data where available.

When an AI health platform like Ones analyzes your blood work alongside wearable trends, it can flag the pattern — low IGF-1 combined with low zinc, low vitamin D, and elevated CRP — and address all three inputs simultaneously rather than treating each in isolation.

Key Takeaways

  • For healthy adults, annual IGF-1 testing is sufficient; quarterly testing without clinical indication produces noise, not insight.
  • For people on GH replacement therapy or managing acromegaly, every 3–6 months per Endocrine Society guidelines is the evidence-based cadence.
  • Symptoms of low IGF-1 — muscle loss, fatigue, poor recovery, cognitive fog — frequently have nutritional causes (low protein, zinc deficiency) that are worth ruling out before assuming pituitary pathology.
  • Symptoms of high IGF-1 — joint pain, glucose dysregulation, excessive sweating — can appear even without frank acromegaly, and persistent high-normal levels warrant a dietary audit and physician review.
  • The 8–12 week retest window after any lifestyle or supplement intervention is the minimum needed to see meaningful, signal-to-noise-clear changes in serum IGF-1.
  • Testing IGF-1 alongside CRP, fasting glucose, and zinc gives a far more complete mechanistic picture than IGF-1 in isolation — these biomarkers sit on intersecting pathways and should ideally be reviewed together.

Written by Jared Murray, Co-Founder & Head of Health Research, Ones.

Jared is the co-founder and head of health research at Ones, with 25 years applying nutrition science, biomarker interpretation, and clinical supplementation research to individual health programs. He leads the editorial process for the Ones Health Library, where lab data, wearable biometrics, and peer-reviewed clinical research are translated into evidence-based, personalized supplement guidance.

Disclosure: Ones formulates and sells personalized supplements that may include ingredients discussed in this article. We have a financial interest in the products mentioned. Recommendations are based on published research and our editorial standards, not sales targets.

This article is educational content, not medical advice. Consult a healthcare provider before changing your supplement regimen.

Further reading

Related reading